Cybersecurity & Cloud Systems

Cloud-Based Systems for Medical Devices: FDA Perspective

April 22, 2024
|
By Dr. Ebot Eyong

The FDA advocates adopting cloud-based systems for medical devices, highlighting benefits such as scalability, enhanced security, collaboration, innovation potential, and operational cost savings. This article explains FDA perspectives and best practices for cloud-based medical device systems.

Overview

The FDA advocates adopting cloud-based systems for medical devices, highlighting key benefits such as scalability, enhanced security, and innovation potential. Utilizing cloud solutions can improve patient care, simplify regulatory compliance, and help reduce operational expenses.

Advantages of Cloud-Based Systems in Medical Devices

  • Scalability and Flexibility: Cloud solutions are designed to manage large volumes of data and can scale resources as necessary, adapting to the evolving needs of healthcare organizations.
  • Enhanced Security: Cloud platforms incorporate security measures like encryption and access controls to protect sensitive patient and device data.
  • Improved Collaboration: These systems facilitate seamless data sharing among healthcare professionals, enabling better coordination and decision-making.
  • Cost Savings: By reducing the need for on-premises infrastructure and ongoing maintenance, cloud solutions help organizations save money.

FDA Guidance on Cloud-Based Medical Devices

  • Premarket Cybersecurity Guidance: The FDA emphasizes cybersecurity throughout the design phase of medical devices, especially those that use cloud-based systems.
  • Post-Market Surveillance: Manufacturers are required to monitor and report cybersecurity vulnerabilities and incidents related to their devices after they have reached the market.

Best Practices for Implementing Cloud-Based Medical Devices

  • Choose a Secure Cloud Platform: Select a cloud platform that complies with FDA regulations and offers robust security features.
  • Implement Cybersecurity Measures: Ensure that cloud-based systems incorporate adequate protection mechanisms, such as encryption and access controls.
  • Perform Regular Security Audits: Conduct consistent reviews of cloud-based systems to identify and address potential security vulnerabilities.

For more information, visit https://eemedicals.com/

Explore More Publications

Continue exploring Dr. Ebot Eyong’s professional insights on healthcare regulation, FDA submissions, AI-enabled medical devices, quality systems, and global compliance strategy.

CMC & FDA Submissions

FDA Guidance for Chemistry, Manufacturing, and Controls (CMC) Submissions

January 15, 2025
|
By Dr. Ebot Eyong

The FDA provides several guidance documents for Chemistry, Manufacturing, and Controls submissions, including post-approval manufacturing changes, comparability protocols, disposable manufacturing materials, nanomaterials, and current good manufacturing practice requirements for combination products.

Read Article

Quality Systems

The FDA's 2025 Draft Guidance is titled "Quality Management System Information for Certain Premarket Submission Reviews

January 2, 2026
|
By Dr. Ebot Eyong

This draft guidance describes a streamlined process for FDA reviewers to evaluate a manufacturer's QMS during premarket review, replacing the disconnected, siloed approach with a proactive use of QMS information to achieve a smoother and more effective review.

Read Article

Real-World Evidence

FDA Update on Real-World Evidence: Implications for AI-Enabled Medical Devices

May 2, 2025
|
By Dr. Ebot Eyong

The U.S. Food and Drug Administration has updated its Real-World Evidence policies to allow greater use of large, well-curated data sources in medical device marketing submissions. This article explains how RWE may support safety and effectiveness for AI-enabled medical devices.

Read Article

AI & Digital Health

FDA Expands Digital Health Exemptions: Implications for AI-Enabled Medical Devices

December 18, 2025
|
By Dr. Ebot Eyong

FDA’s revised digital health guidance expands exemptions for certain low-risk digital health products from active regulatory oversight. This article explains how wearables, wellness products, clinical decision support tools, and AI-enabled software may be affected by the updated risk-based approach.

Read Article